Chugai Pharmaceutical Co., Ltd.
CHGCFOTCHealthcare● Active
$46.93
$-0.79(-1.65%)
Market Cap$77.2B
P/E Ratio—
52W High$68.078
52W Low$39.03
Chugai Pharmaceutical Co., Ltd. (CHGCF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CHGCF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 24, 2026EPS Actual
$0.44
Est. $0.42 · +4.5%
Revenue
$2.03B
Est. $1.98B · +2.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 24, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
CHGCF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$78.12
Rev. $1025.0B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$78.12
Rev. Est.$1025.0B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 24, 2026 | $0.49 | — | — | — | $2.15B | — |
| ▲ Q2 FY2026 | Apr 24, 2026 | $0.42 | $0.44 | +4.5% | $2.03B | $1.98B | +2.3% |
| ▲ Q1 FY2026 | Jan 29, 2026 | $0.47 | $0.50 | +5.5% | $2.21B | $2.08B | +6.4% |
| ▼ Q3 FY2025 | Jul 24, 2025 | $0.51 | $0.41 | -20.7% | $2.00B | $2.20B | -9.0% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $0.34 | $0.41 | +21.7% | $1.98B | $2.26B | -12.2% |
| ▲ Q1 FY2025 | Jan 30, 2025 | $0.00 | $0.36 | +14933.5% | $1.92B | $1.64B | +17.1% |
| ▼ Q4 FY2024 | Oct 25, 2024 | $0.45 | $0.44 | -2.9% | $2.12B | $2.06B | +3.0% |
| ▲ Q3 FY2024 | Jul 25, 2024 | $0.34 | $0.44 | +30.2% | $1.97B | $1.71B | +14.9% |
Q3 FY2026
Jul 24, 2026
EPS Actual
—
EPS Est.
$0.49
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 24, 2026Beat
EPS Actual
$0.44
EPS Est.
$0.42
EPS Surpr.
+4.5%
Revenue
$2.03B
Q1 FY2026
Jan 29, 2026Beat
EPS Actual
$0.50
EPS Est.
$0.47
EPS Surpr.
+5.5%
Revenue
$2.21B
Q3 FY2025
Jul 24, 2025Miss
EPS Actual
$0.41
EPS Est.
$0.51
EPS Surpr.
-20.7%
Revenue
$2.00B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$0.41
EPS Est.
$0.34
EPS Surpr.
+21.7%
Revenue
$1.98B
Q1 FY2025
Jan 30, 2025Beat
EPS Actual
$0.36
EPS Est.
$0.00
EPS Surpr.
+14933.5%
Revenue
$1.92B
Q4 FY2024
Oct 25, 2024Miss
EPS Actual
$0.44
EPS Est.
$0.45
EPS Surpr.
-2.9%
Revenue
$2.12B
Q3 FY2024
Jul 25, 2024Beat
EPS Actual
$0.44
EPS Est.
$0.34
EPS Surpr.
+30.2%
Revenue
$1.97B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $74.78 | $79.38 | $84.47 | 1 |
| Q4 FY2026 | $74.93 | $79.54 | $84.65 | 1 |
| Q3 FY2026 | $77.12 | $81.87 | $87.12 | 1 |
| Q2 FY2026 | $73.42 | $77.94 | $82.94 | 1 |
| Q1 FY2026 | $63.63 | $67.55 | $71.88 | 1 |
| Q4 FY2025 | $73.81 | $74.04 | $74.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $314B | $328B | $345B | 3 |
| Q4 FY2026 | $339B | $354B | $372B | 5 |
| Q3 FY2026 | $351B | $361B | $380B | 6 |
| Q2 FY2026 | $323B | $344B | $360B | 6 |
| Q1 FY2026 | $288B | $317B | $349B | 9 |
| Q4 FY2025 | $295B | $326B | $365B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 24, 2026 | +4.5% | $57.30 | $54.11 | -5.57% |
| ▲ Q1 FY2026 | Jan 29, 2026 | +5.5% | $56.23 | $55.68 | -0.98% |
| ▼ Q3 FY2025 | Jul 24, 2025 | -20.7% | $46.60 | $46.99 | +0.84% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +21.7% | $71.32 | $48.01 | -32.68% |
| ▲ Q1 FY2025 | Jan 30, 2025 | +14933.5% | $38.76 | $32.25 | -16.80% |
| ▼ Q4 FY2024 | Oct 25, 2024 | -2.9% | $43.37 | $43.18 | -0.44% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +30.2% | $35.25 | $35.25 | +0.00% |
| ▲ Q2 FY2024 | Apr 24, 2024 | +5.4% | $33.27 | $32.43 | -2.52% |
Q2 FY2026-5.57%
Report Date
Apr 24, 2026
EPS Beat/Miss
+4.5%
Price Before
$57.30
Price After
$54.11
Q1 FY2026-0.98%
Report Date
Jan 29, 2026
EPS Beat/Miss
+5.5%
Price Before
$56.23
Price After
$55.68
Q3 FY2025+0.84%
Report Date
Jul 24, 2025
EPS Beat/Miss
-20.7%
Price Before
$46.60
Price After
$46.99
Q2 FY2025-32.68%
Report Date
Apr 24, 2025
EPS Beat/Miss
+21.7%
Price Before
$71.32
Price After
$48.01
Q1 FY2025-16.80%
Report Date
Jan 30, 2025
EPS Beat/Miss
+14933.5%
Price Before
$38.76
Price After
$32.25
Q4 FY2024-0.44%
Report Date
Oct 25, 2024
EPS Beat/Miss
-2.9%
Price Before
$43.37
Price After
$43.18
Q3 FY2024+0.00%
Report Date
Jul 25, 2024
EPS Beat/Miss
+30.2%
Price Before
$35.25
Price After
$35.25
Q2 FY2024-2.52%
Report Date
Apr 24, 2024
EPS Beat/Miss
+5.4%
Price Before
$33.27
Price After
$32.43
Avg Beat Reaction-9.76%
Avg Miss Reaction+0.20%
Beat Rate6 / 8 quarters
Largest Move-32.68% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CHGCF ends December
Chugai Pharmaceutical Co., Ltd. (CHGCF) most recently reported earnings on April 24, 2026 for Q2 FY2026, posting EPS of $0.44 — beating the analyst consensus of $0.42 by +4.5%. CHGCF has beaten EPS estimates for 2 consecutive quarters. The next CHGCF earnings date is expected around September 1, 2026.
Each quarter, investors track CHGCF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CHGCF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CHGCF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CHGCF earnings · 5 questionsChugai Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. CHGCF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CHGCF historically reports after market close (AMC).
CHGCF earnings datewhen is CHGCF earningsCHGCF next earnings datewhen does CHGCF report earningsCHGCF earnings calendar
▸ Source: FMP · Chugai Pharmaceutical Co., Ltd. SEC filings · US GAAP · Chugai Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026